RevenanasBook a free audit

Funding

Rhythm expands LG Chem obesity drug license to $855M, secures $750M term loan

Biotech

Funding

Key Facts

Signal Type

Funding

Industry

Biotech

Companies

Rhythm Pharmaceuticals, LG Chem, KKR HealthCare Royalty, Blackstone, William Blair

Date

What Happened

Rhythm Pharmaceuticals and LG Chem revised their licensing agreement for the oral obesity drug bivamelagon, increasing the milestone-based deal from $305 million to $855 million. Under the new terms, Rhythm will pay $350 million in additional payments—$70 million this month, $100 million in September 2027, $100 million in September 2028, and $80 million in September 2029—while lowering royalties to 1% starting in 2029 or upon first commercial sale.

To finance the expanded deal, ongoing commercialization, and R&D, Rhythm entered a $750 million term loan facility with KKR HealthCare Royalty and Blackstone, with $500 million committed. The financing and deal terms reflect strong confidence in the MC4R franchise's multibillion-dollar potential, according to William Blair analyst Alethia Young.

Who Is Affected

Rhythm Pharmaceuticals gains expanded rights and lower long-term costs for a promising oral obesity drug, while LG Chem benefits from increased upfront payments and a potential $200 million payout if sales reach $3 billion. Clinical trial vendors and commercialization service providers should take note: Rhythm's approved injectable Imcivree grew sales 29% to $92.1 million in Q3, and the company is preparing for a Phase 3 pivotal trial of bivamelagon by year-end.

Market Impact

  • Confidence in the pipeline: The expanded deal and financing signal that both Rhythm and LG Chem see the MC4R franchise as a multibillion-dollar opportunity with a long patent runway (Imcivree into 2034, bivamelagon potentially into the 2040s).
  • Validation of management: Analysts view the financing from KKR and Blackstone as a sign of a top-tier management team executing a smart growth strategy.
  • Sales trigger for vendors: A well-funded biotech scaling clinical and commercial operations creates demand for trial management, patient recruitment, data analytics, and commercialization software—immediate outreach opportunities for SDRs.

What to Watch

Rhythm plans to begin a Phase 3 pivotal trial of bivamelagon in hypothalamic obesity by the end of this year, with a study in Prader-Willi syndrome slated for 2027. Monitor Imcivree's sales trajectory and any additional financing or partnership moves as Rhythm executes on its pipeline and expands its commercial footprint.

Related coverage

Get biotech signals in your CRM

FDA approvals and rejections, clinical trial results, pharma M&A, drug recalls, and funding rounds.

Book a 15 min call
Dominykas Rukas - Revenanas

More from this industry

    We can send changes like these to your own CRM, matched to the accounts your team sells to.

    Book a free audit

    Built in your tools.
    Run by your team.

    Tell us the commercial goal and where it gets stuck. We find the bottleneck with you and plan the first two week sprint from it.

    Dominykas Rukas, RevenanasDominykas RukasCo-founderBook a free audit
    • HubSpot partner badgeHubSpot partner
    • Enterprise Clay partner